You Position: Home > Paper

Research progress of Delamani in treatment of multidrug-resistant/extensively drug-resistant tuberculosis

( views:0, downloads:0 )
Author:
No author available
Journal Title:
Chinese Journal of Clinical Infectious Diseases
Issue:
4
DOI:
10.3760/cma.j.issn.1674-2397.2020.04.012
Key Word:
德拉马尼;耐多药结核病;广泛耐药结核病;疗效;安全性;Delamanid;Multidrug-resistant tuberculosis;Extensive drug-resistant tuberculosis;Efficacy;Safety

Abstract´╝Ü The treatment of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) is prone to more time-consuming, complex, toxic and ineffective. MDR-TB has low treatment success rate (52%) and high fatality rate (17%), as well as high rate of lost visits(15%), while the treatment success rate of XDR-TB is only 26%. It’s urgent to develop new drugs and chemotherapy regimens to improve the efficacy for MDR/XDR-TB. Delamanid (Dlm) has a strong killing effect on Mycobacterium tuberculosis (MTB) in vitro and in vivo. When MDR-TB patients are treated with optimized background regimen containing Dlm, the two-month sputum negative conversion rate is increased, case fatality is decreased and the prognosis is improved. This article reviews the progress on characteristics, in vitro activity, animal tests, clinical efficacy and safety of Dlm.

WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn